Michael Charlton, MBBS, is an internationally renowned specialist in liver diseases and transplant medicine. Listed among “America’s Top Doctors” and “Best Doctors in America,” Dr. Charlton has particular expertise in the diagnosis, treatment and management of nonalcoholic fatty liver disease (nonalcoholic steatohepatitis) and viral hepatitis. Dr. Charlton has served as president of the International Liver Transplant Society. He has applied his expertise in editorial roles with leading liver disease and transplantation journals, including associate editor for Hepatology, Transplantation, American Journal of Transplantation and Liver Transplantation. He was also a founding associate editor for Clinical Gastroenterology and Hepatology. Additionally, Dr. Charlton served as a principal investigator on grants and as a study section member for the National Institutes of Health, including studies of the pathophysiology of nonalcoholic fatty liver disease and viral hepatitis. He has published more than 200 manuscripts, and is a lead investigator for national and international clinical trials in viral hepatitis and nonalcoholic fatty liver disease. Dr. Charlton has served as a panel member and writer for the American Association for the Study of Liver Diseases (AASLD) for the management of hepatitis C and also for nonalcoholic steatohepatitis. He is the only physician to serve on both panels. Dr. Charlton was one of the physicians leaders of the transplant care team that made history in December 2018 after performing two triple-organ transplants within 27 hours, replacing the failing hearts, livers and kidneys of 29-year-olds Sarah McPharlin and Daru Smith.